Search
Displaying 1–10 of 779 for “retinitis clinical trial”
-
Sepul Bio completes clinical trial enrollment for its USH2A retinitis pigmentosa treatment
Research NewsUltevursen from Sepul Bio progresses through phase 2b safety and efficacy clinical trial
-
Research News
Marking an important milestone for this rare form of retinitis pigmentosa (RP)
-
Research News
The treatment focuses on the P23H mutation in the RHO gene, which is the most prevalent variant causing adRP in the US and affects approximately 2,500 people.
-
Valproic Acid's Effect Too Small in One-Year Clinical Trial
Research NewsWhile a therapy for adRP will not emerge from the clinical trial, study investigators advanced development of a new outcome measure known as EZ Area to quickly and accurately evaluate potential therapies for RP in human studies.
-
Ocugen to Launch Clinical Trial for Cross-Cutting RP Gene Therapy
Research NewsThe clinical trial is for RHO and NR2E3 mutations, but the retinal gene therapy has the potential to benefit people with a variety of other mutated genes
-
First Patient Receives ProQR’s Emerging USH2A Therapy in Clinical Trial
Research NewsProQR, a developer of RNA therapies in the Netherlands, announced that the first clinical-trial participant has received its emerging treatment, which targets retinitis pigmentosa and Usher syndrome caused by mutations in exon 13 of the USH2A gene.
-
Nacuity’s Antioxidative Therapy NACA Performs Encouragingly in Phase 1/2 Clinical Trial
Research NewsNACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.
-
The Clinical Trial That Opened His World
Beacon StoriesAfter decades of adapting to vision loss from retinitis pigmentosa (RP), Manny Fernandez became one of the first people to receive an experimental gene therapy in a clinical trial. The experience not only restored a small part of his peripheral vision but also renewed his hope for the future and inspired him to encourage others to consider clinical trials, too.
-
Sepul Bio Launches Phase 2b Clinical Trial for USH2A RNA Therapy
Research NewsKnown as ultevursen, the USH2A RNA therapy was licensed from ProQR.
-
AGTC Launches XLRP Gene Therapy Clinical Trial at Five Sites in U.S.
Research NewsTaking place at five locations in the United States, the clinical trial will enroll approximately 15 males with X-linked retinitis pigmentosa caused by mutations in the gene RPGR and will primarily evaluate safety.
.png)
